Clinical trials: Acute Graft Rejection
Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant
The De-novo Use of Eculizumab in Presensitized Patients Receiving Cardiac Transplantation
All individuals who receive a heart transplant are at risk for developing antibody-mediated rejection (AMR). An antibody is a protein produced by the body's immune system when it detects a foreign substance, called an antigen.
- Conditions
- Antibody-mediated Rejection, Hyperacute Rejection of Cardiac Transplant, Left Ventricular Dysfunction, Cardiac Allograft Vasculopathy
- Trial name
- DUET (NCT02013037)
- Testing
- Eculizumab
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Cedars-Sinai Medical Center
Graft Failure, Death
European Transplant Registry of Senior Renal Transplant Recipients on Advagraf
SENIOR transplant Registry European transplant registry of senior renal transplant recipients (above the age of 65 years) receiving initial immunosuppression with tacrolimus once daily, mycophenolate and steroids to investigate…
- Conditions
- Graft Failure, Death, Acute Rejection of Renal Transplant, Infections
- Trial name
- SENIOR (NCT02558452)
- Testing
- Tacrolimus once daily (Advagraf)
- Volunteers
- 1,000 people
- Sponsor
- Klemens Budde
Lung Transplant, End Stage Lung Disease
GRAfT 2.0. A Multimodal Prospective Approach to Define the Mechanisms and Clinical Features of Acute and Chronic Rejection in Lung Transplantation
Background: Lung transplants can save lives, but the procedure has risks. Some people develop donor-specific antibodies (DSA) after the procedure-that is, their bodies create proteins that treat the new lungs as foreign and mount…
- Conditions
- Lung Transplant, End Stage Lung Disease, Rejection
- Trial name
- NCT07516379
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
Kidney Injury, Kidney Failure
Personalization of Immunosuppressive Treatment for Organ Transplant Recipients
Long-term graft failure rates continue to be unacceptably high despite the development of immunosuppressive drugs, underscoring the unmet need for robust prognostic biomarkers of allograft injury and failure.
- Conditions
- Kidney Injury, Kidney Failure, Kidney Failure, Chronic, Kidney Failure, Acute
- Trial name
- STAART (NCT05747053)
- Testing
- AlloSure, PAXGene
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- George Washington University